Ketogenic diet during pelvic cancer radiation treatment
Part of Cancer, Digestive system clinical trials.
This trial studies whether a very low-carbohydrate (ketogenic) diet can be followed safely while you receive neoadjuvant radiation for locally advanced rectal cancer. It may help researchers understand effects related to nutrition and treatment tolerance during radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed rectal adenocarcinoma (a biopsy-proven type of rectal cancer)
- Your rectal cancer is locally advanced (not spread to distant organs)
- You are currently receiving neoadjuvant radiotherapy (radiation given before other treatment)
- You are willing to sign consent for trial participation and personal data use
- You are not severely malnourished by standard screening rules (GLIM)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of a special diet supplement (beta-hydroxybutyrate), short radiation therapy, immunotherapy, and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this approach helps shrink the tumor and improve treatment outcomes.
This trial tests a short course of radiation given before chemotherapy for people with locally advanced rectal cancer (cancer that has grown into nearby tissue and/or nearby lymph nodes but can still be removed). It may help shrink the tumor and make treatment more effective while assessing how well this approach works.
This trial tests whether people with early- to intermediate-stage low rectal cancer can avoid surgery if their tumor responds well to a full course of chemotherapy and radiation. It starts with brief chemotherapy, then adjusts treatment based on how much the tumor shrinks.
This trial tests a shorter course of radiation that avoids draining lymph nodes, followed by an immunotherapy drug (PD-1 inhibitor), for people with stage II or III rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). The goal is to see if this approach can shrink tumors while keeping lymph nodes intact.
This trial tests a special medical food that limits certain amino acids (building blocks of protein) during standard treatment for rectal cancer. The goal is to see if this diet helps the treatment work better while reducing side effects.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy before surgery for high-risk rectal cancer. The goal is to see if this combination shrinks the tumor more effectively and improves outcomes.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.